By Professor Michelle Haber

Journal articles

Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044

Xu N; Tse B; Yang L; Tang TC; Haber M; Micklethwaite K; Dolnikov A, 2021, 'Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy', IMMUNOTARGETS AND THERAPY, 10, pp. 123 - 140, http://dx.doi.org/10.2147/ITT.S296161

Xie J; Kumar A; Dolman MEM; Mayoh C; Khuong-Quang DA; Cadiz R; Wong-Erasmus M; Mould EVA; Grebert-Wade D; Barahona P; Kamili A; Tsoli M; Failes TW; Chow SO; Bhatia K; Marshall GM; Ziegler DS; Haber M; Lock RB; Tyrrell V; Lau L; Athanasatos P; Gifford AJ; Arndt G, 2021, 'The important role of routine cytopathology in pediatric precision oncology', Cancer Cytopathology, 129, pp. 805 - 818, http://dx.doi.org/10.1002/cncy.22448

Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN; Vijayasubhash V, 2021, 'Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma', British Journal of Cancer, 126, pp. 482 - 491, http://dx.doi.org/10.1038/s41416-021-01538-z

Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Hayden E; Rouaen J; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Kankean A; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov A; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS, 2021, 'HGG-09. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG', Neuro-oncology, 23, pp. i18 - i19

Khan A; Gamble L; Upton D; Yu D; Pandher R; Mayoh C; Burns MR; Norris MD; Haber M; Tsoli M; Ziegler DS, 2021, 'RARE-02. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', Neuro-oncology, 23, pp. i40 - i41

Khuong-Quang DA; Brown LM; Wong M; Mayoh C; Sexton-Oates A; Kumar A; Pinese M; Nagabushan S; Lau L; Ludlow LE; Gifford AJ; Rodriguez M; Desai J; Fox SB; Haber M; Ziegler DS; Hansford JR; Marshall GM; Cowley MJ; Ekert PG; Wong-Erasmus M, 2020, 'Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors', Cold Spring Harbor Molecular Case Studies, 6, pp. mcs.a005710, http://dx.doi.org/10.1101/MCS.A005710

Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB, 2020, 'Targeting TSLP-induced tyrosine kinase signaling pathways in CRLF2-Rearranged Ph-like ALL', Molecular Cancer Research, 18, pp. 1767 - 1776, http://dx.doi.org/10.1158/1541-7786.MCR-19-1098

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; Di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris MD; Haber M; Milazzo G; Perini G, 2020, 'Corrigendum to: “MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma” [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235–245] (BBA - Gene Regulatory Mechanisms (2018) 1861(3) (235–245), (S1874939917302894), (10.1016/j.bbagrm.2018.01.007))', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1863, http://dx.doi.org/10.1016/j.bbagrm.2020.194645

Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O’Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ; O'Brien T; Wong-Erasmus M, 2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4

Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ, 2020, 'ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer', International Journal of Cancer, 147, pp. 2225 - 2238, http://dx.doi.org/10.1002/ijc.33005

Hawkins C; Pfister S; Jones DTW; Shah NN; Gilbertson RJ; Sweet-Cordero EA; Dyer MA; Mossé YP; Haber M; DuBois SG, 2020, 'Advances and Challenges in Pediatric and Childhood Cancers', Cancer Cell, 38, pp. 429 - 432, http://dx.doi.org/10.1016/j.ccell.2020.09.013

Voli F; Valli E; Lerra L; Kimpton K; Saletta F; Giorgi FM; Mercatelli D; Rouaen JRC; Shen S; Murray JE; Ahmed-Cox A; Cirillo G; Mayoh C; Beavis PA; Haber M; Trapani JA; Kavallaris M; Vittorio O, 2020, 'Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion', Cancer Research, 80, pp. 4129 - 4144, http://dx.doi.org/10.1158/0008-5472.CAN-20-0471

Gao J; Jung MS; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ, 2020, 'Suppression of ABCE1-mediated mRNA translation limits N-MYC-driven cancer progression', Cancer Research, 80, pp. 3706 - 3718, http://dx.doi.org/10.1158/0008-5472.CAN-19-3914

Salik B; Yi H; Hassan N; Santiappillai N; Vick B; Connerty P; Duly A; Trahair T; Woo AJ; Beck D; Liu T; Spiekermann K; Jeremias I; Wang J; Kavallaris M; Haber M; Norris MD; Liebermann DA; D'Andrea RJ; Murriel C; Wang JY, 2020, 'Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia', Cancer Cell, 38, pp. 263 - 278.e6, http://dx.doi.org/10.1016/j.ccell.2020.05.014

Terry RL; Meyran D; Ziegler DS; Haber M; Ekert PG; Trapani JA; Neeson PJ, 2020, 'Immune profiling of pediatric solid tumors', Journal of Clinical Investigation, 130, pp. 3391 - 3402, http://dx.doi.org/10.1172/JCI137181

Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV, 2020, 'OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis', Leukemia, 34, pp. 1828 - 1839, http://dx.doi.org/10.1038/s41375-019-0692-5

Somers K; Evans K; Cheung L; Karsa M; Pritchard T; Kosciolek A; Bongers A; El-Ayoubi A; Forgham H; Middlemiss S; Mayoh C; Jones L; Gupta M; Kees UR; Chernova O; Korotchkina L; Gudkov AV; Erickson SW; Teicher B; Smith MA; Norris MD; Haber M; Lock RB; Henderson MJ, 2020, 'Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia', Leukemia, 34, pp. 1524 - 1539, http://dx.doi.org/10.1038/s41375-019-0683-6

Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT, 2020, 'Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition', Oncogene, 39, pp. 3555 - 3570, http://dx.doi.org/10.1038/s41388-020-1235-2

Xie J; Span M; van Maarseveen E; Langenhorst J; Boddy AV; Sia KCS; Sutton R; Venn N; Punt AM; Tyrrell V; Haber M; Trahair T; Lau L; Marshall GM; Lock RB, 2020, 'Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia', Pediatric Blood and Cancer, 67, pp. e28133, http://dx.doi.org/10.1002/pbc.28133

Huynh T; Murray J; Flemming CL; Kamili A; Hofmann U; Cheung L; Roundhill EA; Yu DMT; Webber HT; Schwab M; Henderson MJ; Haber M; Norris MD; Fletcher JI, 2020, 'CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth', Biochemical Pharmacology, 172, pp. 113770, http://dx.doi.org/10.1016/j.bcp.2019.113770

Kamili A; Gifford AJ; Li N; Mayoh C; Chow S-O; Failes TW; Eden GL; Cadiz R; Xie J; Lukeis RE; Norris MD; Haber M; McCowage GB; Arndt GM; Trahair TN; Fletcher JI, 2020, 'Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy', British Journal of Cancer, 122, pp. 680 - 691, http://dx.doi.org/10.1038/s41416-019-0682-4

Khan A; Gamble L; Upton D; Yu D; Ehteda A; Pandher R; Mayoh C; Burns M; Norris M; Haber M; Tsoli M; Ziegler D, 2020, 'DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', Neuro-oncology, 22, pp. iii289 - iii290

Khan A; Gamble L; Pandher R; Burns MR; Mussai F; Norris M; Haber M; Tsoli M; Ziegler DS, 2020, 'DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', Neuro-oncology, 22, pp. iii290 - iii290

Ehteda A; Franshaw L; Liu J; Joshi S; Simon S; Pang CNI; Giorgi F; Pandher R; Ung C; Tolhurst O; Mayoh C; Khan A; Hayden E; Gopalakrishnan A; Trebilcock P; Upton D; Lehmann R; George S; Vittorio O; Tsoli M; Gurova K; Gudkov AG; Norris MD; Haber M; Ziegler DS, 2020, 'DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', Neuro-oncology, 22, pp. iii292 - iii292

Wong M; Sun Y; Xi Z; Milazzo G; Poulos RC; Bartenhagen C; Bell JL; Mayoh C; Ho N; Tee AE; Chen X; Li Y; Ciaccio R; Liu PY; Jiang CC; Lan Q; Jayatilleke N; Cheung BB; Haber M; Norris MD; Zhang XD; Marshall GM; Wang JY; Hüttelmaier S; Fischer M; Wong JWH; Xu H; Perini G; Dong Q; George RE; Liu T, 2019, 'JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma', Nature Communications, 10, pp. 3319, http://dx.doi.org/10.1038/s41467-019-11132-w

Liu PY; Tee AE; Milazzo G; Hannan KM; Maag J; Mondal S; Atmadibrata B; Bartonicek N; Peng H; Ho N; Mayoh C; Ciaccio R; Sun Y; Henderson MJ; Gao J; Everaert C; Hulme AJ; Wong M; Lan Q; Cheung BB; Shi L; Wang JY; Simon T; Fischer M; Zhang XD; Marshall GM; Norris MD; Haber M; Vandesompele J; Li J; Mestdagh P; Hannan RD; Dinger ME; Perini G; Liu T, 2019, 'The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35', Nature Communications, 10, pp. 5026, http://dx.doi.org/10.1038/s41467-019-12971-3

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Egolf LE; Way GP; Farrel A; Kendsersky NM; Patel K; Gaonkar KS; Modi A; Berko ER; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni HV; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li XN; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, 2019, 'Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design', Cell Reports, 29, pp. 1675 - 1689.e9, http://dx.doi.org/10.1016/j.celrep.2019.09.071

Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM, 2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112

Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI, 2019, 'MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells', Biochemical Pharmacology, 168, pp. 237 - 248, http://dx.doi.org/10.1016/j.bcp.2019.07.009

Jones DTW; Banito A; Grünewald TGP; Haber M; Jäger N; Kool M; Milde T; Molenaar JJ; Nabbi A; Pugh TJ; Schleiermacher G; Smith MA; Westermann F; Pfister SM, 2019, 'Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours', Nature Reviews Cancer, 19, pp. 420 - 438, http://dx.doi.org/10.1038/s41568-019-0169-x

Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY, 2019, 'MiR-101 suppresses the development of MLL-rearranged acute myeloid leukemia', Haematologica, 104, pp. e296 - e299, http://dx.doi.org/10.3324/haematol.2018.209437

Lynch JR; Salik B; Connerty P; Vick B; Leung H; Pijning A; Jeremias I; Spiekermann K; Trahair T; Liu T; Haber M; Norris MD; Woo AJ; Hogg P; Wang J; Wang JY, 2019, 'JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis', Leukemia, 33, pp. 1400 - 1410, http://dx.doi.org/10.1038/s41375-018-0354-z

Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung MS; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ, 2019, 'A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction', Oncogene, 38, pp. 3824 - 3842, http://dx.doi.org/10.1038/s41388-018-0666-5

Fultang L; Gamble LD; Gneo L; Berry AM; Egan SA; De Bie F; Yogev O; Eden GL; Booth S; Brownhill S; Vardon A; McConville CM; Cheng PN; Norris MD; Etchevers HC; Murray J; Ziegler DS; Chesler L; Schmidt R; Burchill SA; Haber M; De Santo C; Mussai F, 2019, 'Macrophage-derived IL1B and TNFa regulate arginine metabolism in neuroblastoma', Cancer Research, 79, pp. 611 - 624, http://dx.doi.org/10.1158/0008-5472.CAN-18-2139

Dorstyn L; Hackett-Jones E; Nikolic A; Norris MD; Lim Y; Toubia J; Haber M; Kumar S, 2019, 'Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling', Cell Death and Disease, 10, pp. 56, http://dx.doi.org/10.1038/s41419-018-1296-0

Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Giacomo SD; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M, 2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, 11, http://dx.doi.org/10.1126/scitranslmed.aau1099

Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ; Bongers A, 2019, 'Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia', International Journal of Cancer, 146, pp. 1902 - 1916, http://dx.doi.org/10.1002/ijc.32582

Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS; Arndt G, 2018, 'Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer', Cancer Biology and Therapy, 19, pp. 1078 - 1087, http://dx.doi.org/10.1080/15384047.2018.1491498

Jung M; Russell A; Kennedy C; Gifford A; Mallitt K-A; Henderson M; Haber M; Norris M, 2018, 'Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer', JNCI: Cancer Spectrum, 2, pp. pky047, http://dx.doi.org/10.1093/jncics/pky047

Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M; Wong-Erasmus M, 2018, 'Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma', British Journal of Cancer, 119, pp. 693 - 696, http://dx.doi.org/10.1038/s41416-018-0251-2

Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM, 2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034

Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x

Marachelian A; Hogarty MD; Flynn A; Liu K; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer C; Norris M; Haber M; Groshen SG; Ziegler DS; Matthay KK, 2018, 'NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10558

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G, 2018, 'MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1861, pp. 235 - 245, http://dx.doi.org/10.1016/j.bbagrm.2018.01.007

Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P; Mayoh C; Barbaric D; Revesz T; Alvaro F; Pieters R; Haber M; Norris MD; Schrappe M; Dalla Pozza L; Marshall GM, 2018, 'A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children', British Journal of Haematology, 180, pp. 550 - 562, http://dx.doi.org/10.1111/bjh.15056

Khan A; Gamble L; Yu D; Joshi S; Franshaw L; Burns M; Norris M; Haber M; Tsoli M; Ziegler D, 2018, 'DIPG-01. TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', Neuro-oncology, 20, pp. i49 - i49

Murray J; Valli E; Yu DMT; Truong AM; Gifford AJ; Eden GL; Gamble LD; Hanssen KM; Flemming CL; Tan A; Tivnan A; Allan S; Saletta F; Cheung L; Ruhle M; Schuetz JD; Henderson MJ; Byrne JA; Norris MD; Haber M; Fletcher JI, 2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024

Dagg RA; Pickett HA; Neumann AA; Napier CE; Henson JD; Teber ET; Arthur JW; Reynolds CP; Murray J; Haber M; Sobinoff AP; Lau LMS; Reddel RR, 2017, 'Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres', Cell Reports, 19, pp. 2544 - 2556, http://dx.doi.org/10.1016/j.celrep.2017.05.087

Burchill SA; Beiske K; Shimada H; Ambros PF; Seeger R; Tytgat GAM; Brock PR; Haber M; Park JR; Berthold F, 2017, 'Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group', Cancer, 123, pp. 1095 - 1105, http://dx.doi.org/10.1002/cncr.30380

Back to profile page